|
CIBMTR is a research collaboration between the NMDP/Be The Match and Medical College of Wisconsin.
|
|
How to report "B lymphoblastic lymphoma" on CIBMTR Forms
This malignancy is a considered a precursor lymphoid neoplasm and should be reported in the Acute Lymphoblastic Leukemia (ALL) section of the Pre-TED (Form 2400).
The following description comes from the "WHO Classification of Tumors or Hematopoietic and Lymphoid Tissues" (4th Edition):
B lymphoblastic leukemia/lymphoma, NOS is a malignancy of precursor cells (lymphoblasts) committed to the B-cell lineage involving bone marrow (BM) and peripheral blood (PB) (known as B acute lymphoblastic leukemia or ALL) and occasionally presenting with primary involvement of nodal or extranodal sites (known as B lymphoblastic lymphoma or LBL).
The term lymphoma is used when the process is confined to a mass lesion with no or minimal evidence of PB or BM involvement. When there is extensive BM and PB involvement, then lymphoblastic leukemia is the appropriate term.
|
|
Now in the Learning Center
Last month's newsletter provided a link to these two new eLearning modules which will continue to be available from now on through the Learning Center.
CIBMTR Research ID Assignment (Form 2804)
This course explains how to complete the CRID 2804 in FormsNet to register a first-time recipient with CIBMTR. The Learning Objectives are: 1) Understanding the importance of performing a CRID search 2) Editing auto-populated fields 3) Reporting other registry IDs 4) Verifying the NMDP RID, and key points to completing the CRID 2804 accurately.
Indication for CRID Assignment (Form 2814)
Form 2814 collects information to initiate CIBMTR reporting on appropriate research or data collection forms.This course will explain when the form is required and how to complete it.
Each module is approximately 8 minutes in length.
|
Question: Other clinical organ involvement and the grading system for GVHD
Scenario: The recipient has a skin rash covering 30% of their body surface area and elevated AST values. Both are attributed to acute GVHD. The recipient's bilirubin is not elevated at this time. How should I complete the clinical staging and grading questions on the 2100 Form?
Answer:
Other clinical organ involvement should not be used to determine the overall grade of acute GVHD. In the scenario above, the recipient's skin involvement would be reported as skin stage 2. The elevated AST would be reported under "Other clinical organ involvement" and would not be staged. The overall grade of acute GVHD would be determined from the stage of skin involvement alone. Using Table 4: GVHD Grading and Staging (under Question 151) from the Acute Graft vs. Host Disease (GVHD) section of the 100 Day Post-HCT Form (2100) Form Instructions, the center should report the overall Grade of I.
For acute GVHD cases where only other clinical organ involvement is present, the center's response will depend on the form they are completing. On the 2450 (Post-TED) Form, the center should report "Present, grade unknown" in the maximum overall grade data field. On the Post-HCT follow-up forms, 2100, 2200, and 2300, the center should leave the maximum overall grade data field blank and use "unknown" for the validation override code. The center should still report the specific symptoms attributed to GVHD under "Other clinical organ involvement."
Question: Biopsy Reporting
Scenario: A recipient on the CRF track with chronic GVHD diagnosed in the six month reporting period and continuing into the one year reporting period. Diagnosis was confirmed by a biopsy during the six month reporting period. Should biopsy results be reported again in the one year reporting period?
Answer:
No. You only need to report the biopsy results once during the reporting period in which the biopsy was performed. This reporting instruction is the same for acute GVHD; you only report histologic confirmation during the reporting period in which the biopsy was performed.
|
